Sun Pharma Advanced Research Company Limited Total Liabilities
Sun Pharma Advanced Research Company Limited total liabilities. Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) has total liabilities worth Rs6.67 Billion INR (≈ $72.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sun Pharma Advanced Research Company Lim (SPARC) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sun Pharma Advanced Research Company Limited (2007–2025)
Total liabilities of Sun Pharma Advanced Research Company Limited from 2007 to 2025. This chart illustrates how Sun Pharma Advanced Research Company Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Sun Pharma Advanced Research Company Lim long-term investment allocation to see how much of total assets are deployed in long-term investments.
Sun Pharma Advanced Research Company Limited Competitors by Total Liabilities
The table below lists competitors of Sun Pharma Advanced Research Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kvutzat Acro Ltd.
TA:ACRO
|
Israel | ILA4.96 Billion |
|
Inspur Software Co Ltd
SHG:600756
|
China | CN¥1.92 Billion |
|
Weikeng Industrial Co Ltd
TW:3033
|
Taiwan | NT$45.55 Billion |
|
Mega First Corporation Bhd
KLSE:3069
|
Malaysia | RM1.55 Billion |
|
Thurgauer Kantonalbank
SW:TKBP
|
Switzerland | CHF33.13 Billion |
|
COSCO SHIPPING Technology Co Ltd
SHE:002401
|
China | CN¥1.36 Billion |
|
Patria Investments Ltd
NASDAQ:PAX
|
USA | $1.11 Billion |
|
Talkspace Inc
NASDAQ:TALK
|
USA | $19.95 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Sun Pharma Advanced Research Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sun Pharma Advanced Research Company Lim (SPARC) total assets.
Liquidity & Leverage Metrics
Sun Pharma Advanced Research Company Limited Total Liabilities Ratios Explained
Sun Pharma Advanced Research Company Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sun Pharma Advanced Research Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual total liabilities of Sun Pharma Advanced Research Company Limited from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs5.52 Billion ≈ $59.75 Million |
+41.92% |
| 2024-03-31 | Rs3.89 Billion ≈ $42.10 Million |
+22.67% |
| 2023-03-31 | Rs3.17 Billion ≈ $34.32 Million |
+27.52% |
| 2022-03-31 | Rs2.49 Billion ≈ $26.91 Million |
-37.46% |
| 2021-03-31 | Rs3.98 Billion ≈ $43.04 Million |
+36.65% |
| 2020-03-31 | Rs2.91 Billion ≈ $31.49 Million |
+184.82% |
| 2019-03-31 | Rs1.02 Billion ≈ $11.06 Million |
-17.61% |
| 2018-03-31 | Rs1.24 Billion ≈ $13.42 Million |
+8.48% |
| 2017-03-31 | Rs1.14 Billion ≈ $12.37 Million |
-13.84% |
| 2016-03-31 | Rs1.33 Billion ≈ $14.36 Million |
+209.67% |
| 2015-03-31 | Rs428.71 Million ≈ $4.64 Million |
-3.09% |
| 2014-03-31 | Rs442.40 Million ≈ $4.78 Million |
-56.01% |
| 2013-03-31 | Rs1.01 Billion ≈ $10.88 Million |
-33.94% |
| 2012-03-31 | Rs1.52 Billion ≈ $16.46 Million |
+111.81% |
| 2011-03-31 | Rs718.75 Million ≈ $7.77 Million |
+23.68% |
| 2010-03-31 | Rs581.15 Million ≈ $6.28 Million |
+124.60% |
| 2009-03-31 | Rs258.75 Million ≈ $2.80 Million |
+55.03% |
| 2008-03-31 | Rs166.91 Million ≈ $1.81 Million |
+200.36% |
| 2007-03-31 | Rs55.57 Million ≈ $600.96K |
-- |
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more